Full Press Release Details
Bioblast Pharma Reports Third Quarter
2016 Financial Results
Tel Aviv, Israel, - November 29,
2016 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced
financial results for the third quarter ended September 30, 2016.
Key Corporate Highlights:
Third Quarter 2016 Financial results
Bioblast Pharma is a clinical-stage
biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases
with a lead drug candidate, trehalose 90mg/mL solution, in Phase 2 development. Bioblast was founded in 2012 and is traded on the
NASDAQ under the symbol "ORPN". For more information, please visit our website, www.BioblastPharma.com, the content
of which is not incorporated herein by reference.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995
and other Federal securities laws. For example, Bioblast is using forward looking statements when it discusses plans
to conduct a Phase 2b clinical study, the design and timing of such study, and the company's expectation for its cash, cash
equivalents and short-term bank deposits. In addition, historic results of scientific research and clinical and preclinical
trials do not guarantee that the conclusions of future research or trials will suggest similar conclusions or those historic results
referred to in this press release will be interpreted in a similar way in light of additional research and clinical and preclinical
trial results. Any forward-looking statements in this press release are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely
from those set forth in or implied by such forward-looking statements. Because such statements deal with future events and are
based on Bioblast Pharma Ltd.'s current expectations, they are subject to various risks and uncertainties and actual results, performance
or achievements of Bioblast Pharma could differ materially from those described in or implied by the statements in this press release,
including those discussed under the heading "Risk Factors" in Bioblast Pharma's Annual Report on Form 20-F filed with
the Securities and Exchange Commission ("SEC") on March 29, 2016, and in any subsequent filings with the SEC. Except
as otherwise required by law, Bioblast Pharma disclaims any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
LifeSci Advisors, LLC
Telephone: 212-915-0685
Bioblast Pharma Ltd.
Consolidated Statement of Operations
(U.S. dollars in thousands, except share
and per share amounts)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30 | September 30 | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||||
| Research and development | $ | 3,297 | $ | 1,713 | $ | 7,090 | $ | 5,807 | ||||||||
| Pre-commercialization | 39 | 266 | 875 | 266 | ||||||||||||
| General and administrative | 1,242 | 1,608 | 4,827 | 4,570 | ||||||||||||
| Total operating expenses | 4,578 | 3,587 | 12,792 | 10,643 | ||||||||||||
| Loss from operations | (4,578 | ) | (3,587 | ) | (12,792 | ) | (10,643 | ) | ||||||||
| Financial income, net | 8 | 39 | 49 | 115 | ||||||||||||
| Loss before taxes on income | (4,570 | ) | (3,548 | ) | (12,743 | ) | (10,528 | ) | ||||||||
| Taxes on income | 100 | 3 | 206 | 8 | ||||||||||||
| Net loss | $ | (4,670 | ) | $ | (3,551 | ) | $ | (12,949 | ) | $ | (10,536 | ) | ||||
| Net basic and diluted loss per share | $ | (0.28 | ) | $ | (0.25 | ) | $ | (0.82 | ) | $ | (0.74 | ) | ||||
| Weighted average number of Ordinary shares used in computing basic and diluted net loss per share | 16,391,770 | 14,230,480 | 15,752,849 | 14,230,480 |
Bioblast Pharma Ltd.
Consolidated Balance Sheet Data
(U.S. dollars in thousands, except share
| September 30, 2016 | December 31, 2015 | |||||||
| (unaudited) | (audited) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,923 | $ | 7,286 | ||||
| Short-term bank deposits | 7,020 | 12,046 | ||||||
| Receivables and prepaid expenses | 332 | 1,060 | ||||||
| Total current assets | 13,275 | 20,392 | ||||||
| Long-term assets: | ||||||||
| Long-term deposit | 11 | 33 | ||||||
| Property and equipment, net | 84 | 91 | ||||||
| Total long-term assets | 95 | 124 | ||||||
| Total assets | $ | 13,370 | $ | 20,516 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Trade payables | $ | 78 | $ | 1,412 | ||||
| Other accounts payable | 1,921 | 1,102 | ||||||
| Total current liabilities | 1,999 | 2,514 | ||||||
| Long-term liabilities: | ||||||||
| Accrued severance pay | - | 70 | ||||||
| Total long-term liabilities | - | 70 | ||||||
| Shareholders' equity: | ||||||||
| Ordinary shares of NIS 0.01 par value - 50,000,000 shares authorized at September 30, 2016 and December 31, 2015; 16,391,770 issued and outstanding shares at September 30, 2016 and 14,230,480 issued and outstanding shares at December 31, 2015 | 45 | 39 | ||||||
| Additional paid-in capital | 48,062 | 41,680 | ||||||
| Accumulated deficit | (36,736 | ) | (23,787 | ) | ||||
| Total stockholders' equity | 11,371 | 17,932 | ||||||
| Total liabilities and shareholders' equity | $ | 13,370 | $ | 20,516 |
Bioblast Pharma Ltd.
Consolidated Cash Flow Data
(U.S. dollars in thousands)
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2016 | 2015 | |||||||
| (unaudited) | (unaudited) | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (12,949 | ) | $ | (10,536 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 19 | 10 | ||||||
| Stock based compensation, net | 298 | 1,970 | ||||||
| Interest on short-term deposit | (20 | ) | (98 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease (increase) in receivables and prepaid expenses | 728 | (460 | ) | |||||
| Increase in long-term deposit | (3 | ) | (24 | ) | ||||
| Decrease in trade payables | (1,334 | ) | (478 | ) | ||||
| Increase (decrease) in other accounts payable | 819 | (40 | ) | |||||
| Decrease (increase) in accrued severance pay | (70 | ) | 51 | |||||
| Net cash used in operating activities | (12,512 | ) | (9,605 | ) | ||||
| Cash flow from investing activities: | ||||||||
| Withdrawal of short-term bank deposits | 5,046 | 4,000 | ||||||
| Withdrawal of long-term deposits | 25 | - | ||||||
| Purchase of property and equipment | (12 | ) | (31 | ) | ||||
| Net cash provided by investing activities | 5,059 | 3,969 | ||||||
| Cash flow from financing activities: | ||||||||
| Issuance of shares, net | 6,090 | - | ||||||
| Net cash provided by financing activities | 6,090 | - | ||||||
| Decrease in cash and cash equivalents | (1,363 | ) | (5,636 | ) | ||||
| Cash and cash equivalents at the beginning of the period | 7,286 | 10,583 | ||||||
| Cash and cash equivalents at the end of the period | $ | 5,923 | $ | 4,947 |